Omega Therapeutics Long Term Debt

Omega Therapeutics (OMGA) currently reports a long-term debt of $110M as of September 2024. That compares with $110M in the prior-year period — down 2.1% year over year. Use the charts on this page to explore Omega Therapeutics's long-term debt history and peer comparisons.

Omega Therapeutics's long-term debt decreased from $110M to $110M — a 2.1% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Omega Therapeutics reported $110M in long-term debt as of September 2024. That compares with $110M in the prior-year period — down 2.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $110M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Omega Therapeutics, and consider following OMGA for alerts when major investors trade the stock.

Omega Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $110M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OMGA with unrelated industries.